experiments and early clinical trials, neurokinin-1receptor antagonists showed neurokinin-1receptor antagonists showed promise as novel antidepressants. promise as novel antidepressants. Subsequently, however, more extensive Subsequently, however, more extensive clinical trials did not reveal evidence of clinical trials did not reveal evidence of efficacy in depression.The development of efficacy in depression.The development of novel antidepressants will require a better novel antidepressants will require a better understanding of the neural basis of understanding of the neural basis of antidepressant action in humans. antidepressant action in humans.
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For the past 50 years the pharmacological For the past 50 years the pharmacological treatment of depression has rested on treatment of depression has rested on the the use of drugs that potentiate the use of drugs that potentiate the activity activity of monoamines, particularly seroof monoamines, particularly serotonin tonin (5-hydroxytryptamine; 5-HT) and (5-hydroxytryptamine; 5-HT) and noradrenaline. Both the tolerability and noradrenaline. Both the tolerability and efficacy of current treatment is limited efficacy of current treatment is limited and there has been much effort to invent and there has been much effort to invent antidepressant agents with different modes antidepressant agents with different modes of action and improved therapeutic profile. of action and improved therapeutic profile. The difficulties confronting those engaged The difficulties confronting those engaged in this task are well illustrated by the clinin this task are well illustrated by the clinical development of neurokinin-1 (NK ical development of neurokinin-1 (NK 1 1 ) ) receptor antagonists. receptor antagonists.
SUBSTANCE P AND NK SUBSTANCE P AND NK 1 1 RECEPTORS RECEPTORS
Substance P is a neuropeptide that acts as a Substance P is a neuropeptide that acts as a neurotransmitter or neuromodulator within neurotransmitter or neuromodulator within both the central and peripheral nervous sysboth the central and peripheral nervous systems by preferentially binding to the NK tems by preferentially binding to the NK 1 1 receptor. In many brain regions it acts as receptor. In many brain regions it acts as a co-transmitter with 'classical' monoamine a co-transmitter with 'classical' monoamine neurotransmitters such as 5-HT and norneurotransmitters such as 5-HT and noradrenaline. A number of findings from adrenaline. A number of findings from animal studies are consistent with the animal studies are consistent with the notion that substance P and NK notion that substance P and NK 1 1 receptors receptors might be implicated in the pathophysiology might be implicated in the pathophysiology of depression (Kramer of depression (Kramer et al et al, 1998 ). First, , 1998 . First, NK NK 1 1 receptors are found in brain regions receptors are found in brain regions that are implicated in the regulation and exthat are implicated in the regulation and expression of emotion, including the hippopression of emotion, including the hippocampus, amygdala, prefrontal cortex and campus, amygdala, prefrontal cortex and ventral striatum. Second, a variety of ventral striatum. Second, a variety of emotionally unpleasant stimuli, including emotionally unpleasant stimuli, including foot-shock, pain, immobilisation and foot-shock, pain, immobilisation and maternal separation increase substance P maternal separation increase substance P concentrations in limbic regions. Third, concentrations in limbic regions. Third, central administration of substance P central administration of substance P produces behavioural and cardiovascular produces behavioural and cardiovascular responses that resemble those seen responses that resemble those seen following stressful stimuli. Fourth, there is following stressful stimuli. Fourth, there is significant overlap between 5-HT and significant overlap between 5-HT and noradrenaline pathways and substance P noradrenaline pathways and substance P in limbic brain areas, and repeated adminisin limbic brain areas, and repeated administration of traditional antidepressants leads tration of traditional antidepressants leads to decreased synthesis of substance P in to decreased synthesis of substance P in certain brain regions. Fifth, mice in whom certain brain regions. Fifth, mice in whom the NK the NK 1 1 receptor has been knocked out receptor has been knocked out are less anxious; for example, these mice are less anxious; for example, these mice exhibit greater exploration in the open field exhibit greater exploration in the open field test. In addition, NK test. In addition, NK 1 1 receptor knockout receptor knockout mice are more active in the forced swim mice are more active in the forced swim test, an effect similar to that produced by test, an effect similar to that produced by antidepressant treatment in wild-type mice antidepressant treatment in wild-type mice (Santarelli (Santarelli et al et al, 2002) . , 2002). There is little direct evidence in humans There is little direct evidence in humans implicating substance P in depression, but implicating substance P in depression, but substance P levels may be increased in substance P levels may be increased in cerebrospinal fluid in people with cerebrospinal fluid in people with depression who are not on medication depression who are not on medication (Geracioti (Geracioti et al et al, 2006) . A post-mortem , 2006). A post-mortem study of 12 depression patients, 6 of whom study of 12 depression patients, 6 of whom had died by suicide, found lowered NK had died by suicide, found lowered NK 1 1 rereceptor numbers in the orbitofrontal cortex ceptor numbers in the orbitofrontal cortex compared with controls (Stockmeier compared with controls (Stockmeier et al et al, , 2002 ). This could be consistent with 2002). This could be consistent with increased release of substance P. increased release of substance P.
PRECLINICAL STUDIES PRECLINICAL STUDIES OF NK OF NK 1 1 RECEPTOR RECEPTOR ANTAGONISTS ANTAGONISTS
Non-peptide antagonists for the NK Non-peptide antagonists for the NK 1 1 recepreceptor were discovered about 15 years ago and tor were discovered about 15 years ago and several highly specific ligands have been several highly specific ligands have been developed since. As expected, these drugs developed since. As expected, these drugs block the behavioural effects of centrally block the behavioural effects of centrally administered substance P as well as certain administered substance P as well as certain stress-related behaviours in which substress-related behaviours in which substance P has been implicated, for example, stance P has been implicated, for example, vocalisations by guinea pig pups separated vocalisations by guinea pig pups separated from their mothers (Kramer from their mothers (Kramer et al et al, 1998) . , 1998). NK NK 1 1 receptor antagonists are active in receptor antagonists are active in several animal models designed to detect several animal models designed to detect anxiolytic and antidepressant effects. Some anxiolytic and antidepressant effects. Some animal models of anxiety are based on animal models of anxiety are based on unconditioned fear responses; these include unconditioned fear responses; these include the elevated plus maze or open field test, the elevated plus maze or open field test, which measure aversion of rodents to which measure aversion of rodents to novel, brightly lit environments. Similar novel, brightly lit environments. Similar models examine anxiety produced by social models examine anxiety produced by social interaction with unfamiliar conspecifics or interaction with unfamiliar conspecifics or maternal separation. Other tests use condimaternal separation. Other tests use conditioned anxiety responses where a stimulus tioned anxiety responses where a stimulus (for example, a light) becomes aversive (for example, a light) becomes aversive through being paired with a mild electric through being paired with a mild electric foot-shock. Conditioned anxiety models foot-shock. Conditioned anxiety models detect the effects of standard anxiolytics detect the effects of standard anxiolytics such as benzodiazepines. NK such as benzodiazepines. Animal models are also used to detect Animal models are also used to detect potential antidepressant drugs. Some of potential antidepressant drugs. Some of these tests (for example, tail suspension of these tests (for example, tail suspension of mice or the forced swim test in mice and mice or the forced swim test in mice and rats) are used as assays which have proved rats) are used as assays which have proved sensitive to clinically established antisensitive to clinically established antidepressant drugs. Others, employing depressant drugs. Others, employing chronic environmental stressors, attempt chronic environmental stressors, attempt to provide models of depression that have to provide models of depression that have some face validity for the human disorder some face validity for the human disorder and which should therefore be sensitive to and which should therefore be sensitive to both established and novel antidepressant both established and novel antidepressant agents. For example, the chronic mild stress agents. For example, the chronic mild stress model in rats uses a variety of modestly model in rats uses a variety of modestly unpleasant environmental manipulations, unpleasant environmental manipulations, including changes of temperature and including changes of temperature and periods of food and water deprivation, to periods of food and water deprivation, to produce a decrease in the consumption of produce a decrease in the consumption of sucrose solution; this symptom is taken as sucrose solution; this symptom is taken as an analogue of anhedonia and is reversed an analogue of anhedonia and is reversed by chronic treatment with antidepressant by chronic treatment with antidepressant drugs. Social stress and setbacks are known drugs. Social stress and setbacks are known to be associated with depression in humans; to be associated with depression in humans; therefore other animal models use stressful therefore other animal models use stressful social manipulations to produce behavioursocial manipulations to produce behavioural deficits (for example, decreased scent al deficits (for example, decreased scent marking by tree shrews) that are sensitive marking by tree shrews) that are sensitive to antidepressant administration. NK to antidepressant administration. NK 1 1 rereceptor antagonists have antidepressant ceptor antagonists have antidepressant properties in the chronic mild stress and properties in the chronic mild stress and 2 8 2 2 8 2 , in a 6-week trial in about 200 tant), in a 6-week trial in about 200 people with major depression. Participants people with major depression. Participants were randomly allocated under masked were randomly allocated under masked conditions to one of three treatments: apreconditions to one of three treatments: aprepitant 300 mg daily, paroxetine 20 mg daily pitant 300 mg daily, paroxetine 20 mg daily and placebo. Both aprepitant and paroxeand placebo. Both aprepitant and paroxetine were significantly superior to placebo tine were significantly superior to placebo in lowering scores on the Hamilton Rating in lowering scores on the Hamilton Rating Scale for Depression (HRSD) and the HaScale for Depression (HRSD) and the Hamilton Rating Scale for Anxiety. Both acmilton Rating Scale for Anxiety. Both active treatments were of equal efficacy but tive treatments were of equal efficacy but aprepitant was better tolerated than aprepitant was better tolerated than paroxetine, with increased levels of somparoxetine, with increased levels of somnolence the only side-effect compared with nolence the only side-effect compared with placebo. In a further double-blind study of placebo. In a further double-blind study of about 130 out-patients with melancholic about 130 out-patients with melancholic depression, Kramer depression, Kramer et al et al (2004) found that (2004) found that another NK another NK 1 1 receptor antagonist (Lreceptor antagonist (L-759274) also produced a significantly 759274) also produced a significantly greater improvement in HRSD scores than greater improvement in HRSD scores than placebo. placebo.
B R I T I S H J O UR N A L O F P S YC H I AT RY B R I T I S H J O UR N A L O F P SYC HI AT RY
However, these compelling early findHowever, these compelling early findings were not supported by subsequent inings were not supported by subsequent investigations. Keller vestigations. Keller et al et al (2006) reported (2006) reported results from five randomised, double-blind, results from five randomised, double-blind, controlled studies in over 2500 people with controlled studies in over 2500 people with depression. They found that 8 weeks of depression. They found that 8 weeks of treatment with aprepitant at doses of treatment with aprepitant at doses of 80 mg and 160 mg showed no benefit over 80 mg and 160 mg showed no benefit over placebo. In contrast, paroxetine 20 mg placebo. In contrast, paroxetine 20 mg daily, which was used as an active comdaily, which was used as an active comparator in three of the five studies, was parator in three of the five studies, was significantly better than placebo in each significantly better than placebo in each one. Positron emission tomography carried one. Positron emission tomography carried out at the same time indicated that both out at the same time indicated that both doses of aprepitant used in the trials would doses of aprepitant used in the trials would have produced high levels of central NK have produced high levels of central NK 1 1 receptor blockade with occupancy with receptor blockade with occupancy with the 160 mg dose regime being over 95% the 160 mg dose regime being over 95% (Keller (Keller et al et al, 2006) . Given together with , 2006). Given together with dexamethasone and a 5-HT dexamethasone and a 5-HT 3 3 receptor receptor antagonist, aprepitant is licensed at daily antagonist, aprepitant is licensed at daily doses of 80-125 mg for the prevention of doses of 80-125 mg for the prevention of chemotherapy-induced nausea and vomiting; chemotherapy-induced nausea and vomiting; this suggests that the doses employed in the this suggests that the doses employed in the clinical trials of people with depression clinical trials of people with depression would have been pharmacologically active. would have been pharmacologically active.
CONCLUSIONS CONCLUSIONS
More effective and better tolerated antideMore effective and better tolerated antidepressant medications are badly needed for pressant medications are badly needed for the management of major depression; howthe management of major depression; however, the development of the NK ever, the development of the NK 1 1 receptor receptor antagonists as antidepressants shows how antagonists as antidepressants shows how formidable this task is. The NK formidable this task is. The NK 1 1 receptor receptor antagonist aprepitant survived many hurdles antagonist aprepitant survived many hurdles at which candidate antidepressant drugs at which candidate antidepressant drugs may fall. Aprepitant appears safe and well may fall. Aprepitant appears safe and well tolerated and has suitable oral pharmacokitolerated and has suitable oral pharmacokinetics for the treatment of depression. Two netics for the treatment of depression. Two early clinical trials suggested efficacy. early clinical trials suggested efficacy.
A somewhat later, but major problem A somewhat later, but major problem in the development of antidepressant drugs in the development of antidepressant drugs is the high frequency of failed trials in is the high frequency of failed trials in major depression; that is studies where both major depression; that is studies where both an active comparator as well as the coman active comparator as well as the compounds under investigation fail to show pounds under investigation fail to show therapeutic benefits over placebo. However, therapeutic benefits over placebo. However, this was not the case in the studies sumthis was not the case in the studies summarised by Keller marised by Keller et al et al (2006) in which (2006) in which the comparator drug paroxetine was indeed the comparator drug paroxetine was indeed more effective than placebo. However, the more effective than placebo. However, the problem seems to have been rather that problem seems to have been rather that the underlying concept of NK the underlying concept of NK 1 1 receptor anreceptor antagonism as an antidepressant mechanism tagonism as an antidepressant mechanism may have been mistaken. may have been mistaken.
A major underlying problem in the de-A major underlying problem in the development of new antidepressant drugs is velopment of new antidepressant drugs is the reliance on animal models to provide the reliance on animal models to provide proof of concept because we lack valid aniproof of concept because we lack valid animal models of depression. However, even mal models of depression. However, even with conditions such as head injury or with conditions such as head injury or neonatal respiratory distress syndrome, neonatal respiratory distress syndrome, which can be more closely modelled in which can be more closely modelled in animal studies, clear concordance between animal studies, clear concordance between beneficial effects of treatment in animals beneficial effects of treatment in animals and patients is often lacking (Perel and patients is often lacking (Perel et al et al, , 2007) . We suggest that there is a need to 2007). We suggest that there is a need to develop new human models in which develop new human models in which effects of potential antidepressants can be effects of potential antidepressants can be detected. This work requires a much better detected. This work requires a much better understanding of the interaction of antiunderstanding of the interaction of antidepressant drugs with the neural circuitry depressant drugs with the neural circuitry involved in emotional regulation, work involved in emotional regulation, work which modern methods of brain imaging which modern methods of brain imaging is beginning to make possible (see Norbury is beginning to make possible (see Norbury et al et al, 2007) . In addition, with appropriate , 2007). In addition, with appropriate ethical safeguards it should be possible to ethical safeguards it should be possible to carry out proof of concept studies of carry out proof of concept studies of potential antidepressant agents in the most potential antidepressant agents in the most relevant participant groups; that is patients relevant participant groups; that is patients with depression or those at high risk with depression or those at high risk (Bhagwagar (Bhagwagar et al et al, 2004) . , 2004). The possible role of NK The possible role of NK 1 1 receptor anreceptor antagonists in the treatment of emotional distagonists in the treatment of emotional disorders is still an area of active enquiry. The orders is still an area of active enquiry. The early clinical studies suggest that some early clinical studies suggest that some people with depression may benefit, but people with depression may benefit, but identification of potential responders on identification of potential responders on clinical grounds alone seems unlikely to be clinical grounds alone seems unlikely to be successful. NK successful. NK 1 1 receptors have pharmacoreceptors have pharmacological interactions with 5-HT pathways, logical interactions with 5-HT pathways, hence it is conceivable that NK hence it is conceivable that NK 1 1 receptor receptor antagonists might augment the therapeutic antagonists might augment the therapeutic effects of selective serotonin reuptake effects of selective serotonin reuptake inhibitors in depressive and anxiety disinhibitors in depressive and anxiety disorders (Ebner & Singewald, 2006) . Finally orders (Ebner & Singewald, 2006) . Finally it is probably easier to model anxiety than it is probably easier to model anxiety than depression in animals, albeit normal anxidepression in animals, albeit normal anxiety responses to stressors rather than true ety responses to stressors rather than true pathological states. As noted above there pathological states. As noted above there is much evidence from animal studies that is much evidence from animal studies that 
Neurokinin-1 receptors are decreased in major Neurokinin-1 receptors are decreased in major depressive disorder. depressive disorder. NeuroReport NeuroReport, , 13 13, 1223^1227. , 1223^1227.
